The following article was published in Danish pharma industry publication MedWatch on 16 January 2017.
Medigene AG today announced that it has granted an exclusive, worldwide license for the development and commercialization of its preclinical stage adeno-associated virus-like particles (AAVLPs) technology to 2A Pharma AB.[pdf-embedder url="https://2apharma.com/wp-content/uploads/2016/12/Proposal-web-related-2A-Pharma..pdf"]
2A Pharma AB today closed its first financing round, raising SEK 27 million from private angel investors. This new capital will enable us to take our first project, the AAVLP-HPV vaccine, through tothe end of phase I clinical studies. We are grateful for our investors’ support and trust.